CD3/CD19 depleted leukocytes

PreclinicalBiologic

CD3/CD19 depleted leukocytes is one of 94 biologic programs targeting Bone Marrow Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone Marrow TransplantationActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Sickle Cell AnemiaRecruiting

Bone Marrow TransplantationPhase 1/Phase 2

Active, not recruiting

Sickle Cell DiseasePhase 1/Phase 2

Active, not recruiting

Sickle Cell AnemiaPreclinical

Recruiting

Competition

Competitive Landscape

272 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Adakveo

Novartis

Phase 3

7 2

Exjade

Novartis

Phase 3

4 3

Brilinta

AstraZeneca

Phase 3

3 4

Campath

GGenzyme, a Sanofi Company

Phase 3

12 5

Ritalin

Novartis

Phase 3

2 6

Cysteine Hydrochloride

Novartis

Phase 3

2 7

Eliquis

Bristol-Myers Squibb

Phase 3

1 8

Oxbryta

GGlobal Blood Therapeutics

Phase 3

5 9

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 10

Effient

CCosette Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Sickle Cell Anemia

NCT03653338

Q4 2028

Phase 1/2Recruiting

Bone Marrow Transplantation

NCT03500731

Clinical

Trials by Indication[1]

Bone Marrow Transplant1 trial

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

Enrolling by invitation·PPaul Szabolcs·Phase 1/2·NCT01852370·16 enrolled

Bone Marrow Transplantation1 trial

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Recruiting·PPaul Szabolcs·Phase 1/2·NCT03500731·8 enrolled

Sickle Cell Anemia1 trial

T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias

Recruiting·PPaul Szabolcs·Preclinical·NCT03653338·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CD3/CD19 depleted leukocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD3/CD19 depleted leukocytes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD3/CD19 depleted leukocytes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Paul Szabolcs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: PPaul Szabolcs

CD3/CD19 depleted leukocytes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

Bone Marrow Transplant1 trial

Bone Marrow Transplantation1 trial

Sickle Cell Anemia1 trial

References

Drug Info

Quick Facts

Related News